Prophylaxis and Treatment - Reactive Management

Healthcare providers are pivotal in the reactive management of potential drug-drug interactions associated with kinase inhibitor treatment. When a drug-drug interaction occurs, general recommendations include:1

  • Rank the prescribed drugs according to clinical priority. For example, in a patient taking a kinase inhibitor to treat his cancer and also receiving a statin as a preventative treatment, the statin should be interrupted or changed, not the kinase inhibitor
  • Prescribe an alternative, non-interacting, drug
  • Stop the target interacting with the drug temporarily
  • Adjust dose base on known data or extrapolate information to the target drug with close monitoring of toxicity and side effects during follow up
  • Once dosage of two interacting medicines is established clinically, the interaction is considered managed, unless the interacting medicine is stopped or has a dosage change1

Pharmacovigilance

It is important to document unexpected observations and report them to the pharmacovigilance network.2

Further information on the reactive management of drug-drug interactions can be found for each agent.

References

Last update: 17 July 2015